1
|
Sammour T, Peacock O, Bednarski BK, Dasari A, Das P, Johnson B, Smith GL, Chang GJ, Skibber J, You YN. Prospective longitudinal trajectory of cancer survivorship among patients with recurrent rectal cancer: impact of treatment modalities and resection status. Colorectal Dis 2025; 27:e70110. [PMID: 40371878 PMCID: PMC12080081 DOI: 10.1111/codi.70110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/22/2024] [Revised: 02/25/2025] [Accepted: 04/17/2025] [Indexed: 05/16/2025]
Abstract
AIM Recurrent rectal cancer (RRC) can be morbid and optimising cancer survivorship is a priority. The longitudinal trajectories of survivorship associated with RRC have not been prospectively depicted. METHODS We prospectively enrolled patients with RRC. Participants self-reported quality of life (QOL) using validated European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 and CR29, and pain using the Brief Pain Inventory, at baseline and then every 6 months for up to 5 years or until death. Baseline scores and the longitudinal trajectory of scores were examined using linear mixed-effects modelling. RESULTS Among 104 patients, 73 (70.2%) received multimodality salvage treatment with curative intent, while the remainder received best palliative treatments. Curative-intent salvage including surgery was associated with a 30-day operative morbidity rate of 49% and a 5-year overall survival of 51%. Patients undergoing curative-intent salvage versus palliative treatments did not differ in baseline QOL or pain, but the longitudinal trajectory after curative-intent salvage showed sustained improvement of QOL and symptoms over time. This contrasted with the initial transient improvement but persistent decline with palliative treatments. Baseline QOL was significantly impacted by the anatomical site of RRC, with posterior location associated with worst QOL (P = 0.012). Long-term QOL was impacted by anatomical site and status of residual tumour. Pain scores were worse among men. CONCLUSION Trajectories of cancer survivorship for patients with RRC diverge, mainly influenced by anatomical site of the RCC, residual tumour status, and ability to complete curative-intent salvage. These should inform treatment planning. Optimising selection and success of multimodality therapy remains the cornerstone for durable cancer survivorship.
Collapse
Affiliation(s)
- Tarik Sammour
- Department of Colon and Rectal SurgeryUniversity of Texas MD Anderson Cancer CenterHoustonTexasUSA
| | - Oliver Peacock
- Department of Colon and Rectal SurgeryUniversity of Texas MD Anderson Cancer CenterHoustonTexasUSA
| | - Brian K. Bednarski
- Department of Colon and Rectal SurgeryUniversity of Texas MD Anderson Cancer CenterHoustonTexasUSA
| | - Arvind Dasari
- Department of Gastrointestinal Medical OncologyUniversity of Texas MD Anderson Cancer CenterHoustonTexasUSA
| | - Prajnan Das
- Department of Gastrointestinal Radiation OncologyUniversity of Texas MD Anderson Cancer CenterHoustonTexasUSA
| | - Benny Johnson
- Department of Gastrointestinal Medical OncologyUniversity of Texas MD Anderson Cancer CenterHoustonTexasUSA
| | - Grace L. Smith
- Department of Gastrointestinal Radiation OncologyUniversity of Texas MD Anderson Cancer CenterHoustonTexasUSA
- Department of Health Services ResearchUniversity of Texas MD Anderson Cancer CenterHoustonTexasUSA
| | - George J. Chang
- Department of Colon and Rectal SurgeryUniversity of Texas MD Anderson Cancer CenterHoustonTexasUSA
- Department of Health Services ResearchUniversity of Texas MD Anderson Cancer CenterHoustonTexasUSA
| | - John Skibber
- Department of Colon and Rectal SurgeryUniversity of Texas MD Anderson Cancer CenterHoustonTexasUSA
| | - Y. Nancy You
- Department of Colon and Rectal SurgeryUniversity of Texas MD Anderson Cancer CenterHoustonTexasUSA
| |
Collapse
|
2
|
Schellack SK, Breidenbach C, Kowalski C, Wedding U, van Oorschot B, Seufferlein T, Benz S, Schnell M, Köninger J, Klein C, Ockenga J, Freitag B, Wittel UA, Wahba R, Kim M, Elhabash S, Piso P, Weyhe D, Bunse J, Riechmann M, von Strauss M, Petzoldt S, Neumann PA, Kolb V, Sibert NT. Pain and overall quality of life in palliatively treated colorectal cancer patients 1 year after diagnosis- results from the EDIUM cohort. J Cancer Res Clin Oncol 2025; 151:127. [PMID: 40164841 PMCID: PMC11958386 DOI: 10.1007/s00432-025-06186-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2025] [Accepted: 03/24/2025] [Indexed: 04/02/2025]
Abstract
PURPOSE Diagnosis with UICC stage IV colorectal cancer often indicates palliative treatment to alleviate symptoms. Data on pain in these patients are still scarce but can help improve symptom management. This study therefore aimed to describe patient-reported pain and quality of life. METHODS 147 palliatively treated stage IV colorectal cancer patients diagnosed between 2018 and 2023 completed the EORTC QLQ-C30 and QLQ-CR29 before and 12 months after treatment initiation within the EDIUM study. Descriptive results for pain and quality of life were examined and compared to reference values. A logistic regression analysis investigated the relationship between quality of life and pain and 1-year survival. RESULTS The mean (SD) for the "overall pain" score was 26 (32) (T0) and 35 (32) (T1) for rectal cancer patients and 34 (33) (T0) and 35 (32) (T1) for colon cancer patients. This is higher than the reference value (24 (30)) and indicates high average pain levels. The "overall quality of life" score showed means below the reference value (61 (23)), indicating poorer quality of life (colon: 51 (25) (T0), 56 (22) (T1); rectum: 52 (24) (T0), 51 (22) (T1)). Higher pain levels persisted at both time points, with no patients reporting absence of pain. The logistic regression results suggest a small relationship between pain and quality of life and 1-year survival. DISCUSSION This study reveals high levels of pain among palliatively treated colorectal cancer patients, impacting their quality of life. Effective pain management and close monitoring are necessary to improve the quality of life for these patients. TRAIL NUMBER DRKS00008724.
Collapse
Affiliation(s)
| | - Clara Breidenbach
- German Cancer Society, Kuno-Fischer-Straße 8, 14057, Berlin, Germany
| | | | - Ulrich Wedding
- University Medicine Jena, Kastanienstraße 1, 07747, Jena, Germany
| | | | | | - Stefan Benz
- Klinikum Sindelfingen-Böblingen, Calwer Straße 68, 71034, Böblingen, Germany
| | - Martin Schnell
- Hegau-Bodensee-Klinikum Singen, Virchowstr. 10, 78224, Singen, Germany
| | - Jörg Köninger
- Klinikum Stuttgart, Kriegsbergstraße 60, 70174, Stuttgart, Germany
| | - Christina Klein
- Helios Park-Klinikum Leipzig, Strümpellstraße 41, 04289, Leipzig, Germany
| | - Johann Ockenga
- Bremen Klinikum Bremen-Mitte, Sankt-Jürgen-Str. 1, 28205, Bremen, Germany
| | - Björn Freitag
- St. Josef-Hospital, Gudrunstraße 56, 44791, Bochum, Germany
| | - Uwe A Wittel
- Kliniken Nordoberpfalz- Klinikum Weiden, Söllnerstraße 16, 92637, Weiden in der Oberpfalz, Germany
| | - Roger Wahba
- Helios Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125, Berlin, Germany
| | - Mia Kim
- München Klinik Neuperlach, Sanatoriumspl. 2, 81545, München, Germany
| | - Saleem Elhabash
- Johannes Wesling Klinikum Minden, Hans-Nolte-Straße 1, 32429, Minden, Germany
| | - Pompiliu Piso
- Barmherzige Brüder Regensburg, Prüfeninger Str. 86, 93049, Regensburg, Germany
| | - Dirk Weyhe
- Pius Hospital University Medicine Oldenburg, Georgstraße 12, 26121, Oldenburg, Germany
| | - Jörg Bunse
- Sana Klinikum Lichtenberg, Fanningerstraße 32, 10365, Berlin-Lichtenberg, Germany
| | - Maren Riechmann
- Sana Klinikum Hof, Hochfranken, Eppenreuther Straße 9, 95032, Hof, Germany
| | - Marco von Strauss
- St. Claraspital Basel, Kleinriehenstrasse 30, Basel, 4058, Switzerland
| | - Sebastian Petzoldt
- DRK Kliniken Berlin-Treptow- Köpenick, Salvador-Allende-Str. 2- 8, 12559, Berlin, Germany
| | | | - Vanessa Kolb
- OnkoZert GmbH, Gartenstraße 24, Neu-Ulm, Germany
| | - Nora Tabea Sibert
- German Cancer Society, Kuno-Fischer-Straße 8, 14057, Berlin, Germany.
- Oncological Health Services Research with a focus on Digital Medicine, Department of Gynaecology and Obstetrics, CIO ABCD, University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Moorenstraße 5, Düsseldorf, Germany.
| |
Collapse
|
3
|
Haas S, Mikkelsen AH, Kronborg CJS, Oggesen BT, Møller PF, Fassov J, Frederiksen NA, Krogsgaard M, Graugaard-Jensen C, Ventzel L, Christensen P, Emmertsen KJ. Management of treatment-related sequelae following colorectal cancer. Colorectal Dis 2023; 25:458-488. [PMID: 35969031 DOI: 10.1111/codi.16299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/29/2022] [Revised: 07/15/2022] [Accepted: 07/21/2022] [Indexed: 02/08/2023]
Abstract
AIM Colorectal cancer survivors are one of the most rapidly growing groups of patients living with and beyond cancer. In a national multidisciplinary setting, we have examined the extent of late treatment-related sequelae in colorectal cancer survivors and present the scientific evidence for management of these conditions in this patient category with the aim of facilitating identification and treatment. METHOD A systematic search for existing guidelines and relevant studies was performed across 16 and 4 databases, respectively, from inception to 2021. This yielded 13 guidelines and 886 abstracts, of which 188 were included in the finalized guideline (231 included for full text review). Secondarily, bibliographies were cross-referenced and 53 additional articles were included. RESULTS Symptoms have been divided into overall categories including psychosocial, bowel-related, urinary, sexual (male and female), pain/neuropathy and fatigue symptoms or complaints that are examined individually. Merging and grading of data resulted in 22 recommendations and 42 management strategies across categories. Recommendations are of a more general character, whereas management strategies provide more practical advice suited for initiation on site before referral to specialized units. CONCLUSION Treatment-related sequelae in colorectal cancer survivors are common and attention needs to be focused on identifying patients with unmet treatment needs and the development of evidence-based treatment algorithms.
Collapse
Affiliation(s)
- Susanne Haas
- Department of Surgery, Danish Cancer Society National Research Center for Survivorship and Late Adverse Effects Following Pelvic Organ Cancer, Aarhus University Hospital, Aarhus, Denmark
- Department of Surgery, Randers Regional Hospital, Randers, Denmark
| | | | | | | | - Pia F Møller
- Department of Surgery, Vejle Hospital, Vejle, Denmark
| | - Janne Fassov
- Department of Surgery, Danish Cancer Society National Research Center for Survivorship and Late Adverse Effects Following Pelvic Organ Cancer, Aarhus University Hospital, Aarhus, Denmark
- Department of Gastroenterology and Hepatology, Aarhus University Hospital, Aarhus, Denmark
| | | | | | | | - Lise Ventzel
- Department of Oncology, University Hospital of Southern Denmark, Vejle, Denmark
| | - Peter Christensen
- Department of Surgery, Danish Cancer Society National Research Center for Survivorship and Late Adverse Effects Following Pelvic Organ Cancer, Aarhus University Hospital, Aarhus, Denmark
- Department of Surgery, Aarhus University Hospital, Aarhus, Denmark
| | - Katrine Jøssing Emmertsen
- Department of Surgery, Danish Cancer Society National Research Center for Survivorship and Late Adverse Effects Following Pelvic Organ Cancer, Aarhus University Hospital, Aarhus, Denmark
- Department of Surgery, Randers Regional Hospital, Randers, Denmark
| |
Collapse
|
4
|
Al-Obaidi M, Kosmicki S, Harmon C, Lobbous M, Outlaw D, Khushman M, McGwin G, Bhatia S, Giri S, Williams GR. Pain among older adults with gastrointestinal malignancies- results from the cancer and aging resilience evaluation (CARE) Registry. Support Care Cancer 2022; 30:9793-9801. [PMID: 36329186 DOI: 10.1007/s00520-022-07398-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2022] [Accepted: 08/02/2022] [Indexed: 11/06/2022]
Abstract
PURPOSE The impact of pain on functional status and mental health among older adults with cancer is a relevant, yet understudied. We sought to identify the prevalence of pain at diagnosis in older adults with gastrointestinal (GI) malignancies and evaluate the association of pain with functional status limitations, cognition, and mental health. METHODS This prospective cross-sectional study included older adults (age ≥ 60) with GI cancers enrolled in the CARE Registry. Pain measured in numeric rating scale from 0 to 10. We utilized the literature based cutoff for moderate-severe as ≥ 4. Logistic regression used to assess differences in functional status, falls, cognitive complaints, and depression/anxiety associated with moderate/severe pain, adjusted for sex, race, education, ethnicity, marital status, cancer type/stage, and treatment phase. RESULTS Our cohort included 714 older adults with an average mean age of 70 years and 59% male. Common diagnoses included colorectal (27.9%) and pancreatic (18%). A total of 43.3% reported moderate/severe pain. After multivariate adjusting for covariates, participants with self-reported moderate/severe pain were more likely to report limitations in instrumental activities of daily living (adjusted odds ratio [aOR] 4.3 95% confidence interval [CI] 3.1-6.1, p < .001), limitation in activities of daily living (aOR 3.2 95% CI 2.0-5.1, p < .001), cognitive complaints (aOR 2.9 95% CI 1.4-6.0, p < .004), anxiety (aOR 2.2 95% CI 1.4-3.4, p < 0.01), and depression (aOR 3.7 95% CI 2.2-6.5, p < .001). CONCLUSIONS Pain is common among older adults with GI cancers and is associated with functional status limitations, cognitive complaints, and depression/anxiety. Strategies to reduce pain and minimize its potential impact on function and mental health warrant future research.
Collapse
Affiliation(s)
- Mustafa Al-Obaidi
- Institute for Cancer Outcomes & Survivorship, University of Alabama at Birmingham, 1600 7th Avenue South, Lowder 500, Birmingham, AL, 35233, USA.
| | - Sarah Kosmicki
- Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Christian Harmon
- Institute for Cancer Outcomes & Survivorship, University of Alabama at Birmingham, 1600 7th Avenue South, Lowder 500, Birmingham, AL, 35233, USA
| | - Mina Lobbous
- Department of Neurology, Division of Neuro-Oncology, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Darryl Outlaw
- O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Moh'd Khushman
- O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Gerald McGwin
- Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Smita Bhatia
- Institute for Cancer Outcomes & Survivorship, University of Alabama at Birmingham, 1600 7th Avenue South, Lowder 500, Birmingham, AL, 35233, USA
- O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Smith Giri
- Institute for Cancer Outcomes & Survivorship, University of Alabama at Birmingham, 1600 7th Avenue South, Lowder 500, Birmingham, AL, 35233, USA
- O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Grant R Williams
- Institute for Cancer Outcomes & Survivorship, University of Alabama at Birmingham, 1600 7th Avenue South, Lowder 500, Birmingham, AL, 35233, USA
- O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA
| |
Collapse
|
5
|
Tan CJ, Yip SYC, Chan RJ, Chew L, Chan A. Investigating how cancer-related symptoms influence work outcomes among cancer survivors: a systematic review. J Cancer Surviv 2022; 16:1065-1078. [PMID: 34424498 PMCID: PMC9489549 DOI: 10.1007/s11764-021-01097-5] [Citation(s) in RCA: 30] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2021] [Accepted: 08/09/2021] [Indexed: 01/07/2023]
Abstract
PURPOSE The purpose of this study is to investigate how different cancer-related symptoms influence work outcomes among cancer survivors. METHODS A literature search was performed in PubMed, EMBASE, CINAHL, PsycINFO, and Scopus to identify studies published between 1st January 1999 and 30th October 2020 that investigated the impact of specific cancer-related symptoms on work outcomes among cancer survivors who have completed primary antineoplastic treatment. Study findings were extracted and grouped by symptoms and work outcomes, allowing comparison of associations between these outcomes. RESULTS Seventy-three articles representing 68 studies were eligible for inclusion. From these studies, 27 cancer-related symptoms, 9 work outcomes, and 68 unique associations between specific symptoms and work outcomes were identified. Work status (return to work and employment rates) was most commonly studied, and symptom burden was mainly measured from the patient's perspective. Higher symptom burden was generally associated with trends of poorer work outcomes. Significant associations were reported in most studies evaluating body image issues and work status, oral dysfunction and work status, fatigue and work ability, and depression and work ability. CONCLUSION Several cancer-related symptoms were consistently associated with inferior work outcomes among cancer survivors. Body image issues and oral dysfunction were shown to be associated with poorer employment rates, while fatigue and depression were linked to lower levels of work performance. IMPLICATIONS FOR CANCER SURVIVORS Failure to return to work and decreased productivity post-cancer treatment can have negative consequences for cancer survivors and society at large. Findings from this review will guide the development of work rehabilitation programs for cancer survivors. PROTOCOL REGISTRATION PROSPERO identifier CRD42020187754.
Collapse
Affiliation(s)
- Chia Jie Tan
- Department of Pharmacy, National University of Singapore, Singapore, Singapore
| | | | - Raymond Javan Chan
- Caring Futures Institute, College of Nursing and Health Sciences, Flinders University, Adelaide, South Australia, Australia
| | - Lita Chew
- Department of Pharmacy, National University of Singapore, Singapore, Singapore
- Department of Pharmacy, National Cancer Centre Singapore, Singapore, Singapore
| | - Alexandre Chan
- Department of Pharmacy, National Cancer Centre Singapore, Singapore, Singapore.
- Department of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California, 101 Theory, Suite 100, Irvine, CA, 92612, USA.
| |
Collapse
|
6
|
Renna ME, Shrout MR, Madison AA, Alfano CM, Povoski SP, Lipari AM, Carson WE, Malarkey WB, Kiecolt-Glaser JK. Depression and anxiety in colorectal cancer patients: TIES TO PAIN, FATIGUE, AND INFLAMMATION. Psychooncology 2022; 31:1536-1544. [PMID: 35751505 DOI: 10.1002/pon.5986] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2022] [Revised: 06/04/2022] [Accepted: 06/17/2022] [Indexed: 11/10/2022]
Abstract
OBJECTIVE Colorectal cancer poses a significant threat to both psychological and physical health. This study examined relationships between anxiety and depressive symptoms with pain, fatigue, and inflammation among colorectal patients. METHODS Colorectal cancer patients (n = 88, stages 0-IV) completed a laboratory-based study visit before undergoing adjuvant cancer treatment. Patients completed questionnaires assessing depressive, anxiety, pain, and fatigue symptoms. A blood sample was also collected to measure c-reactive protein (CRP). Analyses controlled for age, sex, cancer stage, body mass index (BMI), and menopause status. RESULTS Multiple linear regression analyses showed colorectal patients with higher depressive and anxiety symptoms had greater pain, fatigue, and CRP (ps < .03). Approximately one-third of patients with clinically significant depressive (CESD > 16) and anxiety symptoms (BAI > 16) also had clinically-elevated levels of CRP ( > 3mg/L) (ps = .02). CONCLUSION These results extend findings from other cancer subgroups showing heightened symptom burden among patients with depression and anxiety. They also highlight the detrimental role that elevated anxiety and depressive symptoms may play in the physical and biological side effects associated with colorectal cancer. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Megan E Renna
- School of Psychology, University of Southern Mississippi, Hattiesburg, MS, USA
| | - M Rosie Shrout
- Department of Human Development & Family Studies, Purdue University, Lafayette, IN, USA
| | - Annelise A Madison
- Institute for Behavioral Medicine Research, The Ohio State University College of Medicine, Columbus, OH, USA.,Department of Psychology, The Ohio State University, Columbus, OH, USA
| | | | - Stephen P Povoski
- Comprehensive Cancer Center, The Ohio State University College of Medicine, Columbus, OH, USA.,Department of Surgery, The Ohio State University College of Medicine, Columbus, OH, USA
| | - Adele M Lipari
- Comprehensive Cancer Center, The Ohio State University College of Medicine, Columbus, OH, USA.,Department of Surgery, The Ohio State University College of Medicine, Columbus, OH, USA
| | - William E Carson
- Comprehensive Cancer Center, The Ohio State University College of Medicine, Columbus, OH, USA.,Department of Surgery, The Ohio State University College of Medicine, Columbus, OH, USA
| | - William B Malarkey
- Institute for Behavioral Medicine Research, The Ohio State University College of Medicine, Columbus, OH, USA.,Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH, USA
| | - Janice K Kiecolt-Glaser
- Institute for Behavioral Medicine Research, The Ohio State University College of Medicine, Columbus, OH, USA.,Department of Psychiatry and Behavioral Health, The Ohio State University College of Medicine, Columbus, OH, USA
| |
Collapse
|
7
|
Halpern MT, de Moor JS, Yabroff KR. Impact of Pain on Employment and Financial Outcomes Among Cancer Survivors. J Clin Oncol 2022; 40:24-31. [PMID: 34292791 PMCID: PMC9851709 DOI: 10.1200/jco.20.03746] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
PURPOSE Although pain is a frequently reported symptom among individuals with cancer, there is limited information on the impact of pain on employment or financial outcomes. This study used nationally representative data to examine the role of pain levels on employment and financial outcomes. METHODS We used data from the 2016-2017 Medical Expenditure Panel Survey Experiences with Cancer Survivorship Supplement to identify 1,213 adults diagnosed with cancer. Multivariable logistic regression analyses were used to examine association of pain levels and self-reported employment and financial outcomes. RESULTS Approximately 43% of adults with a cancer history reported no pain, 29% mild pain, 18% moderate pain, and 10% severe pain over the past 7 days. Compared with those reporting no pain, individuals reporting any pain had significantly increased likelihood of adverse employment outcomes including early retirement, feeling less productive, and staying at a job because of concerns about losing insurance. Individuals with any pain (compared with no pain) also had significantly increased likelihood of adverse financial outcomes including borrowing money or going into debt, inability to cover medical costs, and worrying about paying medical bills. For both employment and financial outcomes, there were dose-response relationships, with worse outcomes generally associated with greater pain levels. CONCLUSION Pain is frequently associated with adverse employment and financial outcomes among cancer survivors, and greater pain is associated with worse outcomes. Better assessment of pain severity among survivors and implementation of strategies to assist with employment and financial objectives may be important steps to enhance patient-centered care.
Collapse
Affiliation(s)
- Michael T. Halpern
- Healthcare Delivery Research Program, National Cancer Institute, Bethesda, MD,Michael T. Halpern, MD, PhD, Healthcare Delivery Research Program, National Cancer Institute, 9609 Medical Center Dr, Room 3E342, Bethesda, MD 20892-9762; e-mail:
| | - Janet S. de Moor
- Healthcare Delivery Research Program, National Cancer Institute, Bethesda, MD
| | - K. Robin Yabroff
- Department of Surveillance and Health Equity Science, American Cancer Society, Atlanta, GA
| |
Collapse
|
8
|
Farrukh N, Hageman L, Chen Y, Wu J, Ness E, Kung M, Francisco L, Parman M, Landier W, Arora M, Armenian S, Bhatia S, Williams GR. Pain in older survivors of hematologic malignancies after blood or marrow transplantation: A BMTSS report. Cancer 2020; 126:2003-2012. [PMID: 32022263 DOI: 10.1002/cncr.32736] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2019] [Revised: 12/17/2019] [Accepted: 12/28/2019] [Indexed: 11/07/2022]
Abstract
BACKGROUND Blood or marrow transplantation (BMT) is increasingly offered to older adults with hematologic malignancies; however, their risk for severe pain is poorly understood. Using the Bone Marrow Transplant Survivor Study, the current study investigated the prevalence and predictors of pain after BMT (allogeneic or autologous) as well as its association with physical performance impairments and frailty. METHODS The cohort included 736 patients with hematologic malignancies who underwent BMT at an age ≥ 60 years at 1 of 3 transplant centers between 1974 and 2014 and survived ≥2 years after BMT; 183 unaffected siblings also participated. Study participants reported on 4 pain domains (nonminor everyday pain, moderate to severe bodily pain, prolonged pain, and moderate to extreme pain interference), and the presence of 1 or more domains was indicative of a severe and/or life-interfering pain composite variable. RESULTS Overall, 39.4% of the BMT survivors reported severe pain with 2.6-fold greater odds of reporting pain in comparison with sibling controls. Among BMT recipients, those with less education, lower incomes, and active chronic graft-versus-host disease had higher odds of reporting pain. In multivariable analyses, BMT survivors with pain were more likely to have impaired physical performance and were more likely to meet the frailty criteria. BMT survivors reported higher use of pain medications (17.8% vs 9.3%) and opioid pain medications (6.5% vs 2.2%) in comparison with sibling controls. CONCLUSIONS Nearly 40% of older BMT survivors who were followed for a median of 5 years after BMT reported pain, and BMT survivors had 2.6-fold higher odds of reporting severe, nonminor or life-interfering pain in comparison with siblings.
Collapse
Affiliation(s)
- Naveed Farrukh
- Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, Alabama
| | - Lindsey Hageman
- Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, Alabama
| | - Yanjun Chen
- Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, Alabama
| | - Jessica Wu
- Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, Alabama
| | - Emily Ness
- Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, Alabama
| | - Michelle Kung
- Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, Alabama
| | - Liton Francisco
- Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, Alabama
| | - Mariel Parman
- Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, Alabama
| | - Wendy Landier
- Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, Alabama
| | - Mukta Arora
- University of Minnesota, Minneapolis, Minnesota
| | | | - Smita Bhatia
- Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, Alabama
| | - Grant R Williams
- Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, Alabama
| |
Collapse
|
9
|
Thinh DHQ, Sriraj W, Mansor M, Tan KH, Irawan C, Kurnianda J, Nguyen YP, Ong-Cornel A, Hadjiat Y, Moon H, Javier FO. Analgesic Prescription Patterns and Pain Outcomes in Southeast Asia: Findings From the Analgesic Treatment of Cancer Pain in Southeast Asia Study. J Glob Oncol 2019; 4:1-10. [PMID: 30241271 PMCID: PMC6223410 DOI: 10.1200/jgo.17.00055] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose To identify patterns of analgesic prescription and to explore patient-reported pain intensity, sleep disturbance, and quality of life among cancer patients with pain in Southeast Asia (SEA). Methods This cross-sectional observational study included 465 adult outpatients prescribed analgesics for cancer pain for 1 month or longer at 22 sites in Indonesia, Malaysia, Philippines, Singapore, Thailand, and Vietnam. Data on analgesic prescription and cancer characteristics were extracted from medical records. Pain intensity, sleep disturbance, and quality of life measures were recorded via questionnaires. Results Most patients (84.4%) had stage III or IV cancer. A total of 419 patients (90.7%) were prescribed opioids; of these, 42.2% received only weak opioids, whereas 57.8% received at least one strong opioid. The mean worst pain intensity during the past 24 hours was 4.76 (standard deviation [SD], 2.47) on a scale of 0 (no pain) to 10 (worst possible pain); the mean current pain intensity was 4.10 (SD, 2.61). More than half of patients (54.8%) reported sleep disturbance caused by pain in the past 7 days. The majority of patients reported problems with pain/discomfort (82.3%), usual activities (65.8%), mobility (58.2%), and anxiety/depression (56.3%). The median daily dose prescribed in oral morphine equivalents was 30 mg for both morphine and tramadol. Conclusion Despite unrelieved pain, sleep disturbance, and issues with quality of life, a notable proportion of patients were prescribed only weak opioids, and opioid doses prescribed were generally low. Efforts focused on encouragement of prescriptions with analgesic strength and/or doses proportional to the pain management needs of patients are vital to improve the status of cancer pain management in the region.
Collapse
Affiliation(s)
- Dang Huy Quoc Thinh
- Dang Huy Quoc Thinh, Ho Chi Minh City Oncology Hospital, Ho Chi Minh City; Yen Phi Nguyen, Vietnam National Cancer Hospital, Hanoi, Vietnam; Wimonrat Sriraj, Srinagarind Hospital, Khon Kaen, Thailand; Marzida Mansor, University of Malaya, Kuala Lumpur, Malaysia; Kian Hian Tan, Singapore General Hospital; Yacine Hadjiat and Hanlim Moon, APAC LATAM MEA, Mundipharma, Singapore; Cosphiadi Irawan, Cipto Mangunkusumo General Hospital, Universitas of Indonesia, Jakarta Pusat; Johan Kurnianda, Dr Sardjito General Hospital, Yogyakarta, Indonesia; Annielyn Ong-Cornel, Veterans' Memorial Medical Centre; and Francis O. Javier, St Luke's Medical Center, Quezon City, Philippines
| | - Wimonrat Sriraj
- Dang Huy Quoc Thinh, Ho Chi Minh City Oncology Hospital, Ho Chi Minh City; Yen Phi Nguyen, Vietnam National Cancer Hospital, Hanoi, Vietnam; Wimonrat Sriraj, Srinagarind Hospital, Khon Kaen, Thailand; Marzida Mansor, University of Malaya, Kuala Lumpur, Malaysia; Kian Hian Tan, Singapore General Hospital; Yacine Hadjiat and Hanlim Moon, APAC LATAM MEA, Mundipharma, Singapore; Cosphiadi Irawan, Cipto Mangunkusumo General Hospital, Universitas of Indonesia, Jakarta Pusat; Johan Kurnianda, Dr Sardjito General Hospital, Yogyakarta, Indonesia; Annielyn Ong-Cornel, Veterans' Memorial Medical Centre; and Francis O. Javier, St Luke's Medical Center, Quezon City, Philippines
| | - Marzida Mansor
- Dang Huy Quoc Thinh, Ho Chi Minh City Oncology Hospital, Ho Chi Minh City; Yen Phi Nguyen, Vietnam National Cancer Hospital, Hanoi, Vietnam; Wimonrat Sriraj, Srinagarind Hospital, Khon Kaen, Thailand; Marzida Mansor, University of Malaya, Kuala Lumpur, Malaysia; Kian Hian Tan, Singapore General Hospital; Yacine Hadjiat and Hanlim Moon, APAC LATAM MEA, Mundipharma, Singapore; Cosphiadi Irawan, Cipto Mangunkusumo General Hospital, Universitas of Indonesia, Jakarta Pusat; Johan Kurnianda, Dr Sardjito General Hospital, Yogyakarta, Indonesia; Annielyn Ong-Cornel, Veterans' Memorial Medical Centre; and Francis O. Javier, St Luke's Medical Center, Quezon City, Philippines
| | - Kian Hian Tan
- Dang Huy Quoc Thinh, Ho Chi Minh City Oncology Hospital, Ho Chi Minh City; Yen Phi Nguyen, Vietnam National Cancer Hospital, Hanoi, Vietnam; Wimonrat Sriraj, Srinagarind Hospital, Khon Kaen, Thailand; Marzida Mansor, University of Malaya, Kuala Lumpur, Malaysia; Kian Hian Tan, Singapore General Hospital; Yacine Hadjiat and Hanlim Moon, APAC LATAM MEA, Mundipharma, Singapore; Cosphiadi Irawan, Cipto Mangunkusumo General Hospital, Universitas of Indonesia, Jakarta Pusat; Johan Kurnianda, Dr Sardjito General Hospital, Yogyakarta, Indonesia; Annielyn Ong-Cornel, Veterans' Memorial Medical Centre; and Francis O. Javier, St Luke's Medical Center, Quezon City, Philippines
| | - Cosphiadi Irawan
- Dang Huy Quoc Thinh, Ho Chi Minh City Oncology Hospital, Ho Chi Minh City; Yen Phi Nguyen, Vietnam National Cancer Hospital, Hanoi, Vietnam; Wimonrat Sriraj, Srinagarind Hospital, Khon Kaen, Thailand; Marzida Mansor, University of Malaya, Kuala Lumpur, Malaysia; Kian Hian Tan, Singapore General Hospital; Yacine Hadjiat and Hanlim Moon, APAC LATAM MEA, Mundipharma, Singapore; Cosphiadi Irawan, Cipto Mangunkusumo General Hospital, Universitas of Indonesia, Jakarta Pusat; Johan Kurnianda, Dr Sardjito General Hospital, Yogyakarta, Indonesia; Annielyn Ong-Cornel, Veterans' Memorial Medical Centre; and Francis O. Javier, St Luke's Medical Center, Quezon City, Philippines
| | - Johan Kurnianda
- Dang Huy Quoc Thinh, Ho Chi Minh City Oncology Hospital, Ho Chi Minh City; Yen Phi Nguyen, Vietnam National Cancer Hospital, Hanoi, Vietnam; Wimonrat Sriraj, Srinagarind Hospital, Khon Kaen, Thailand; Marzida Mansor, University of Malaya, Kuala Lumpur, Malaysia; Kian Hian Tan, Singapore General Hospital; Yacine Hadjiat and Hanlim Moon, APAC LATAM MEA, Mundipharma, Singapore; Cosphiadi Irawan, Cipto Mangunkusumo General Hospital, Universitas of Indonesia, Jakarta Pusat; Johan Kurnianda, Dr Sardjito General Hospital, Yogyakarta, Indonesia; Annielyn Ong-Cornel, Veterans' Memorial Medical Centre; and Francis O. Javier, St Luke's Medical Center, Quezon City, Philippines
| | - Yen Phi Nguyen
- Dang Huy Quoc Thinh, Ho Chi Minh City Oncology Hospital, Ho Chi Minh City; Yen Phi Nguyen, Vietnam National Cancer Hospital, Hanoi, Vietnam; Wimonrat Sriraj, Srinagarind Hospital, Khon Kaen, Thailand; Marzida Mansor, University of Malaya, Kuala Lumpur, Malaysia; Kian Hian Tan, Singapore General Hospital; Yacine Hadjiat and Hanlim Moon, APAC LATAM MEA, Mundipharma, Singapore; Cosphiadi Irawan, Cipto Mangunkusumo General Hospital, Universitas of Indonesia, Jakarta Pusat; Johan Kurnianda, Dr Sardjito General Hospital, Yogyakarta, Indonesia; Annielyn Ong-Cornel, Veterans' Memorial Medical Centre; and Francis O. Javier, St Luke's Medical Center, Quezon City, Philippines
| | - Annielyn Ong-Cornel
- Dang Huy Quoc Thinh, Ho Chi Minh City Oncology Hospital, Ho Chi Minh City; Yen Phi Nguyen, Vietnam National Cancer Hospital, Hanoi, Vietnam; Wimonrat Sriraj, Srinagarind Hospital, Khon Kaen, Thailand; Marzida Mansor, University of Malaya, Kuala Lumpur, Malaysia; Kian Hian Tan, Singapore General Hospital; Yacine Hadjiat and Hanlim Moon, APAC LATAM MEA, Mundipharma, Singapore; Cosphiadi Irawan, Cipto Mangunkusumo General Hospital, Universitas of Indonesia, Jakarta Pusat; Johan Kurnianda, Dr Sardjito General Hospital, Yogyakarta, Indonesia; Annielyn Ong-Cornel, Veterans' Memorial Medical Centre; and Francis O. Javier, St Luke's Medical Center, Quezon City, Philippines
| | - Yacine Hadjiat
- Dang Huy Quoc Thinh, Ho Chi Minh City Oncology Hospital, Ho Chi Minh City; Yen Phi Nguyen, Vietnam National Cancer Hospital, Hanoi, Vietnam; Wimonrat Sriraj, Srinagarind Hospital, Khon Kaen, Thailand; Marzida Mansor, University of Malaya, Kuala Lumpur, Malaysia; Kian Hian Tan, Singapore General Hospital; Yacine Hadjiat and Hanlim Moon, APAC LATAM MEA, Mundipharma, Singapore; Cosphiadi Irawan, Cipto Mangunkusumo General Hospital, Universitas of Indonesia, Jakarta Pusat; Johan Kurnianda, Dr Sardjito General Hospital, Yogyakarta, Indonesia; Annielyn Ong-Cornel, Veterans' Memorial Medical Centre; and Francis O. Javier, St Luke's Medical Center, Quezon City, Philippines
| | - Hanlim Moon
- Dang Huy Quoc Thinh, Ho Chi Minh City Oncology Hospital, Ho Chi Minh City; Yen Phi Nguyen, Vietnam National Cancer Hospital, Hanoi, Vietnam; Wimonrat Sriraj, Srinagarind Hospital, Khon Kaen, Thailand; Marzida Mansor, University of Malaya, Kuala Lumpur, Malaysia; Kian Hian Tan, Singapore General Hospital; Yacine Hadjiat and Hanlim Moon, APAC LATAM MEA, Mundipharma, Singapore; Cosphiadi Irawan, Cipto Mangunkusumo General Hospital, Universitas of Indonesia, Jakarta Pusat; Johan Kurnianda, Dr Sardjito General Hospital, Yogyakarta, Indonesia; Annielyn Ong-Cornel, Veterans' Memorial Medical Centre; and Francis O. Javier, St Luke's Medical Center, Quezon City, Philippines
| | - Francis O Javier
- Dang Huy Quoc Thinh, Ho Chi Minh City Oncology Hospital, Ho Chi Minh City; Yen Phi Nguyen, Vietnam National Cancer Hospital, Hanoi, Vietnam; Wimonrat Sriraj, Srinagarind Hospital, Khon Kaen, Thailand; Marzida Mansor, University of Malaya, Kuala Lumpur, Malaysia; Kian Hian Tan, Singapore General Hospital; Yacine Hadjiat and Hanlim Moon, APAC LATAM MEA, Mundipharma, Singapore; Cosphiadi Irawan, Cipto Mangunkusumo General Hospital, Universitas of Indonesia, Jakarta Pusat; Johan Kurnianda, Dr Sardjito General Hospital, Yogyakarta, Indonesia; Annielyn Ong-Cornel, Veterans' Memorial Medical Centre; and Francis O. Javier, St Luke's Medical Center, Quezon City, Philippines
| |
Collapse
|
10
|
McDermott KA, Joyner KJ, Hakes JK, Okey SA, Cougle JR. Pain interference and alcohol, nicotine, and cannabis use disorder in a national sample of substance users. Drug Alcohol Depend 2018; 186:53-59. [PMID: 29550622 DOI: 10.1016/j.drugalcdep.2018.01.011] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/10/2017] [Revised: 01/04/2018] [Accepted: 01/11/2018] [Indexed: 10/17/2022]
Abstract
BACKGROUND Pain interference is associated with substance use, but has yet to be considered as a potential indicator of SUDs among substance users. We sought to examine whether moderate and high pain interference would confer risk for SUDs in ever and weekly users. METHODS Using data from the National Epidemiologic Survey on Alcohol and Related Conditions, logistic regression analyses were conducted to examine the association between pain interference and concurrent and prospective alcohol and nicotine dependence, as well as concurrent cannabis use disorder. Those with no/low pain were used as the reference group. Gender was examined as a moderator. RESULTS Controlling for relevant covariates, moderate pain interference was associated with past year alcohol (odds ratio [OR] = 1.33, 95% CI, 1.16-1.52, p < .001) and nicotine (OR = 1.41, 95% CI 1.27-1.56, p < .001) dependence among ever users. In prospective analyses, moderate pain interference predicted the development of alcohol (Moderate: OR = 1.56, 95% CI, 1.39-1.75, p < .001) and nicotine (OR = 1.37, 95% CI, 1.14-1.65, p < .001) dependence. Similar results were found with high pain and for weekly users. Both moderate and high pain interference were associated with past-year occurrence of cannabis use disorder for women but not men. High pain predicted the development of nicotine dependence exclusively among males. CONCLUSION Pain interference may confer risk for the occurrence of cannabis use disorder among female cannabis users and the occurrence and development of alcohol and nicotine dependence among users of both genders. Pain interference may be an important factor to monitor in these populations.
Collapse
Affiliation(s)
| | - Keanan J Joyner
- Department of Psychology, Florida State University, Tallahassee, FL, USA
| | - Jahn K Hakes
- Center for Administrative Records Research and Applications, US Census Bureau, Suitland, MD, USA
| | - Sarah A Okey
- Department of Psychology, Florida State University, Tallahassee, FL, USA
| | - Jesse R Cougle
- Department of Psychology, Florida State University, Tallahassee, FL, USA
| |
Collapse
|
11
|
Ho KY, Ahn JS, Calimag MM, Chao TC, Kim YC, Moon H, Tho LM, Xia ZJ, You D. Inadequate treatment practices for pain relief and adverse event management in cancer patients across 10 countries/regions in Asia: a call for greater efforts to improve standards for patient care. Asia Pac J Clin Oncol 2017; 14:159-166. [PMID: 28670820 DOI: 10.1111/ajco.12696] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2016] [Accepted: 03/30/2017] [Indexed: 12/11/2022]
Abstract
AIM To examine the treatment practices for cancer pain relief and adverse event management, and the factors related to patient outcomes in the participating countries/regions. METHODS The study was a cross-sectional survey conducted between September and December 2013 in 10 countries/regions across Asia. Adult patients with a history of cancer pain at least 1 month before study entry completed the survey questionnaire. RESULTS A total of 1190 patients were included. The mean Box Scale-11 (BS-11) pain score was 6.0 (SD 2.1), with 86.2% experiencing moderate-to-severe pain and 53.2% receiving opioids at time of the survey. The mean BS-11 scores were 5.3 (SD 2.1) in the "others" (single non-opioid medication or untreated) group, 6.3 (SD 2.0) in the ≥2 non-opioids group and 6.7 (SD 1.9) in the opioid group. The proportions of patients experiencing moderate-to-severe pain were 79.1%, 87.3% and 93.7%, respectively. About 70% of patients reported adverse events due to their pain medications, about half had received medications to manage these symptoms. Adverse events were negatively associated with activities of daily living (P < 0.0001). Pain and hindrance to activities of daily living were negatively associated with employment status (P = 0.003 and 0.021). Unemployment was significantly associated with poorer quality of life (P < 0.0001). CONCLUSION This analysis demonstrates inadequate management of cancer pain and treatment-related adverse events in the participating cohort. Pain and inadequate management of adverse events were negatively associated with patients' overall well-being. More collaborative efforts should be taken to optimize pain treatment and increase awareness of adverse event management in physicians.
Collapse
Affiliation(s)
- Kok Yuen Ho
- Pain Management Service, Raffles Hospital, Singapore
| | - Jin Seok Ahn
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Maria Minerva Calimag
- Departments of Pharmacology, Clinical Epidemiology and Anesthesiology, University of Santo Tomas Faculty of Medicine and Surgery and the UST Hospital, Manila, Philippines
| | - Ta-Chung Chao
- Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan, R.O.C.,Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C
| | - Yong-Chul Kim
- Department of Anesthesiology and Pain Medicine, Seoul National University School of Medicine, Seoul, Korea
| | | | - Lye Mun Tho
- Department of Clinical Oncology, Beacon International Specialist Centre, Selangor, Malaysia
| | - Zhong-Jun Xia
- Sun Yat-Sen University Cancer Center, Guangzhou, China
| | | |
Collapse
|
12
|
Gauthier LR, Dworkin RH, Warr D, Pillai Riddell R, Macpherson AK, Rodin G, Zimmermann C, Lawrence Librach S, Moore M, Shepherd FA, Gagliese L. Age-Related Patterns in Cancer Pain and Its Psychosocial Impact: Investigating the Role of Variability in Physical and Mental Health Quality of Life. PAIN MEDICINE 2017; 19:658-676. [DOI: 10.1093/pm/pnx002] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Affiliation(s)
- Lynn R Gauthier
- School of Kinesiology and Health Science
- Department of Supportive Care
- School of Kinesiology and Health Science
| | - Robert H Dworkin
- Departments of Anesthesiology and Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
| | - David Warr
- Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre
- Department of Medicine
| | - Rebecca Pillai Riddell
- Department of Psychology, York University, Toronto, Ontario, Canada
- Department of Psychiatry
- Department of Psychiatry, The Hospital for Sick Children, Toronto, Ontario, Canada
| | | | - Gary Rodin
- Department of Supportive Care
- Department of Medicine
- Department of Psychiatry
| | - Camilla Zimmermann
- Department of Supportive Care
- Department of Medicine
- Department of Psychiatry
| | - S Lawrence Librach
- Family and Community Medicine, Division of Palliative Care, University of Toronto, Toronto, Ontario, Canada
- Mount Sinai Hospital, Toronto, Ontario, Canada
| | - Malcolm Moore
- British Columbia Cancer Agency, Vancouver, British Columbia, Canada
| | - Frances A Shepherd
- Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre
- Department of Medicine
| | - Lucia Gagliese
- School of Kinesiology and Health Science
- Department of Anesthesia, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada
- Department of Supportive Care
- Department of Psychiatry
- Mount Sinai Hospital, Toronto, Ontario, Canada
| |
Collapse
|
13
|
Drury A, Payne S, Brady AM. The cost of survival: an exploration of colorectal cancer survivors' experiences of pain. Acta Oncol 2017; 56:205-211. [PMID: 28068155 DOI: 10.1080/0284186x.2016.1266084] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
BACKGROUND The Institute of Medicine report 'From Cancer Patient to Cancer Survivor' has drawn widespread attention to the experiences of cancer survivors. Research examining the symptom experiences of survivors are proliferative within the literature but limited by samples which include multiple tumor groups and varying inclusion criteria. This cross-sectional quantitative study seeks to examine pain and quality of life (QoL) in the context of colorectal cancer (CRC) survivorship, as defined by the Institute of Medicine. MATERIAL AND METHODS A purposive sample of CRC survivors (n = 252) attending hospitals and cancer support centers in the Republic of Ireland were recruited between September 2014 and January 2016. Self-rated health (SRH), QoL and pain were assessed in the sample using the EuroQOL questionnaire, the Functional Assessment of Therapy-Colorectal (FACT-C) questionnaire, and symptom experience items. RESULTS One hundred participants (40%) indicated they had pain on the day of the survey or in the past week. Of those with pain, many also experienced a lack of energy (95%), bowel dysfunction (74%), sleep disturbance (76%) or interference with their ability to enjoy life (75%). Pain was associated with younger age, female gender, current chemotherapy treatment, and previous radiotherapy treatment. Although participants reported positive QoL scores, statistical analysis revealed pain was linked to significantly poorer SRH and overall QoL, and poorer physical, emotional, functional, social/family and CRC-specific wellbeing, compared to those who did not indicate pain. DISCUSSION Pain was experienced by almost two fifths of CRC survivors up to five years after treatment and was associated with poorer SRH and QoL. In light of these findings, healthcare professionals must endeavor to manage cancer survivors' needs in a manner which is cognizant of the burden of pain and in the context of other symptoms and morbidities experienced by long-term cancer survivors.
Collapse
Affiliation(s)
- Amanda Drury
- School of Nursing & Midwifery, Faculty of Health Sciences, Trinity College Dublin, Dublin, Ireland
| | - Sheila Payne
- International Observatory on End of Life Care, Division of Health Research, Lancaster University, Lancaster, UK
| | - Anne-Marie Brady
- School of Nursing & Midwifery, Faculty of Health Sciences, Trinity College Dublin, Dublin, Ireland
| |
Collapse
|
14
|
Jean-Pierre P, McDonald B. Neuroepidemiology of cancer and treatment-related neurocognitive dysfunction in adult-onset cancer patients and survivors. Neuroepidemiology 2016; 138:297-309. [DOI: 10.1016/b978-0-12-802973-2.00017-3] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
|
15
|
Wang CH, Lee SYC. Undertreatment of caner pain. ACTA ACUST UNITED AC 2015; 53:58-61. [PMID: 26063333 DOI: 10.1016/j.aat.2015.05.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2015] [Accepted: 05/06/2015] [Indexed: 11/30/2022]
Abstract
Pain is a burdensome symptom that can commonly exist chronically along the cancer trajectory. Uncontrolled pain will impact on cancer patients' quality of life, even further negatively affect cancer survivors' employment. Based on systemic reviews of studies for past 10 years, the paper reported that although there is enormous advancement on the knowledge of cancer pain and pain management, studies still documented undertreatment of cancer pain globally. Additionally, pain distress a significant portion of cancer survivors. The pain in cancer survivors distinct from the pain related with cancer, instead emphasize on pain related with cancer treatment, such as neuropathic pain, muscular syndrome. Evidence-based pain management with common pain problems in cancer survivors is lacking. Further studies are needed to understand the pain in cancer survivors and to develop effective strategies in helping cancer survivors to manage their pain.
Collapse
Affiliation(s)
- Cheng-Hsu Wang
- National Taipei University of Nursing and Health Sciences, Taipei, Taiwan.
| | - Shiu-Yu C Lee
- Chang Gung Memorial Hospital, Clinic of Internal Medicine, Division of Hematology-Oncology, Department of Internal Medicine, Keelung, Taiwan
| |
Collapse
|